MSB Mesoblast Ltd
- 1.045
- +0.020+1.95%
Mesoblast Ltd News
ASX Growth Companies With High Insider Ownership And At Least 26% Earnings Growth
Amidst a generally downward trend in the ASX200, with notable dips in sectors like materials and utilities, there are still segments showing resilience, such as industrials.
ASX Growth Leaders With High Insider Ownership To Watch
The Australian market has shown robust growth, climbing 1.1% over the past week and achieving a 9.4% increase over the last year, with earnings expected to grow by 14% annually.
Insider Still Buying Mesoblast Shares Despite 230% Rise This Year: Should You Buy?
Mesoblast Ltd (ASX: MSB) shares have been among the best performers on the Australian share market this year.
Why Is the Mesoblast Share Price Taking a Dive on Tuesday?
The Mesoblast Ltd (ASX: MSB) share price is under pressure on Tuesday.
Mesoblast Could Now Generate Meaningful FY 2025 Revenue -- Market Talk
0448 GMT - Mesoblast keeps its speculative buy rating from Bell Potter despite its recent share-price surge, with analyst John Hester flagging the potential for meaningful revenue generation in fiscal
Mesoblast Price Target Raised to A$1.40/Share From A$0.58 by Bell Potter
Mesoblast Price Target Raised to A$1.40/Share From A$0.58 by Bell Potter
Blast Off! Mesoblast Share Price Surging 60%
Top ASX Shares to Buy in April 2024
If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index (ASX: XJO) so far in 2024, fear not!
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission
The US Food and Drug Administration has notified Mesoblast (ASX:MSB) that available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support the submission of the proposed Biolog
Mesoblast Up Over 59%, on Pace for Largest Percent Increase Since April 2020 -- Data Talk
Mesoblast Limited Sponsored ADR (MESO) is currently at $3.50, up $1.31 or 59.32% --Would be highest close since Aug. 3, 2023, when it closed at $7.75 --On pace for largest percent increase since Apr
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application
By Dean Seal Mesoblast's American depositary receipts surged after the company got the go-ahead from regulators to submit a biologics license application for its remestemcel-L treatment for pediatric
Mesoblast Price Target Raised 14% to A$0.80/Share by Jefferies
Mesoblast Price Target Raised 14% to A$0.80/Share by Jefferies
Mesoblast Raises AU$97 Million for Phase Three Registration Trials
Mesoblast (ASX:MSB) raised AU$97 million via an entitlement offer and institutional placement. The proceeds included AU$36.7 million committed on Thursday on the same terms as the entitlement offer, m
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer).
Mesoblast Secures Backing From US FDA for Potential Fast-Track Approval of Heart Failure Treatment
Mesoblast (ASX:MSB) secured guidance from the US Food and Drug Administration for proposed regulatory pathways for its rexlemestrocel-L cell therapy, according to a filing with the Australian Securiti
Mesoblast Price Target Raised 17% to A$0.70/Share by Jefferies
Mesoblast Price Target Raised 17% to A$0.70/Share by Jefferies
Mesoblast Narrows H1 FY24 Loss; Shares Down 3%
Mesoblast (ASX:MSB) reported Thursday that it narrowed its loss per share in the six-month period ended Dec. 31, 2023, to $0.0382 from the prior-year period's $0.0564. Revenue was $3.39 million, inchi
Press Release: Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
Mesoblast Secures US FDA Orphan Drug Designation for Cell Therapy; Shares Jump 7%
Mesoblast (ASX:MSB) secured an orphan drug designation from the US Food and Drug Administration for the use of its Revascor allogenic cell therapy in pediatric patients with hypoplastic left heart syn
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023.
Analysis
Price Target
No Data
